INC. (NASDAQ:INCR) Files An 8-K Results of Operations and Financial ConditionItem 2.02
Results of Operations and Financial Condition.
On February 2, 2018, Walker Innovation Inc. issued a press release announcing financial results for the three and twelve months ended December 31, 2017. The full text of the press release is set forth in Exhibit 99.1 attached hereto.
The information in this Form 8-K, including the exhibit, shall not be deemed to be “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that Section. It shall not be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, except as shall be expressly set forth by specific reference in such a filing.
|
Item 9.01 |
Financial Statements and Exhibits. |
|
Exhibit Number |
Description |
|
99.1 |
Press Release datedFebruary 2, 2018 |
WALKER INNOVATION INC. ExhibitEX-99.1 2 ex_103581.htm EXHIBIT 99.1 ex_103581.htm Exhibit 99.1 WALKER INNOVATION ANNOUNCES FOURTH QUARTER AND FULL YEAR 2017 RESULTS $24 Million of Cash as of December 31,…To view the full exhibit click here
About INC. (NASDAQ:INCR)
INC Research Holdings, Inc. is a global contract research organization (CRO). The Company is focused on Phase I to Phase IV clinical development services for the biopharmaceutical and medical device industries. The Company operates through two segments: Clinical Development Services and Phase I Services. The Company’s Clinical Development Services segment offers all clinical development services, including full-service global studies, as well as ancillary services, such as clinical monitoring, investigator recruitment, patient recruitment, data management, study reports to assist customers with their drug development process, quality assurance audits and specialized consulting services. The Company’s Phase I Services segment focuses on clinical development services for Phase I trials, which include scientific exploratory medicine, first-in-human studies through proof-of-concept stages and support for Phase I studies in established compounds.